Compare CVGI & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVGI | PRLD |
|---|---|---|
| Founded | 2000 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.5M | 69.1M |
| IPO Year | 2004 | 2020 |
| Metric | CVGI | PRLD |
|---|---|---|
| Price | $2.90 | $3.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.67 |
| AVG Volume (30 Days) | ★ 873.1K | 318.9K |
| Earning Date | 06-15-2026 | 06-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 316.18 | 23.21 |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $755,231,000.00 | $12,140,000.00 |
| Revenue This Year | N/A | $320.10 |
| Revenue Next Year | $8.47 | $100.00 |
| P/E Ratio | $58.25 | ★ N/A |
| Revenue Growth | 14.06 | ★ 73.43 |
| 52 Week Low | $0.81 | $0.61 |
| 52 Week High | $2.62 | $4.19 |
| Indicator | CVGI | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 78.78 | 60.16 |
| Support Level | $1.49 | $0.99 |
| Resistance Level | N/A | $4.19 |
| Average True Range (ATR) | 0.21 | 0.36 |
| MACD | 0.10 | 0.05 |
| Stochastic Oscillator | 100.00 | 54.79 |
Commercial Vehicle Group Inc is a provider of systems, assemblies, and components to the commercial vehicle market and the electric vehicle markets. It delivers solutions to complex design, engineering, and manufacturing problems while creating positive change for customers, industries, and communities. Its operating segments are Vehicle Solutions, Electrical Systems, and Aftermarket and Accessories. The company makes the majority of its revenue from Vehicle Solutions. The group generates revenue from its products including seating systems, plastic components, electrical wire harnesses, mirrors, wipers, and other accessories. Its geographic regions are North America, Europe and Asia-Pacific.
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.